Tenofovir/Emtricitabine and efavirenz — Competitive Intelligence Brief

Tenofovir/Emtricitabine and efavirenz (Tenofovir/Emtricitabine and efavirenz) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI + NNRTI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (NRTI + NNRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Tenofovir/Emtricitabine and efavirenz (Tenofovir/Emtricitabine and efavirenz) — GlaxoSmithKline. This combination inhibits HIV reverse transcriptase and integrase to block viral replication and reduce viral load in HIV-infected patients.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tenofovir/Emtricitabine and efavirenz TARGET	Tenofovir/Emtricitabine and efavirenz	GlaxoSmithKline	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase
Nevirapine, FTC, and Tenofovir	Nevirapine, FTC, and Tenofovir	University of Maryland, Baltimore	marketed	Antiretroviral combination (NNRTI + NRTI + NtRI)	HIV reverse transcriptase, HIV integrase
Bictegravir, emtricitabine, and tenofovir alafenamide	Bictegravir, emtricitabine, and tenofovir alafenamide	CAN Community Health	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Tenofovir + emtricitabine + lopinavir/ritonavir	Tenofovir + emtricitabine + lopinavir/ritonavir	Juan A. Arnaiz	marketed	Antiretroviral combination (NRTI + protease inhibitor)	HIV reverse transcriptase, HIV protease
Tenofovir alafenamide/emtricitabine	Tenofovir alafenamide/emtricitabine	ViiV Healthcare	marketed	Nucleotide/nucleoside reverse transcriptase inhibitor combination	HIV reverse transcriptase
Darunavir, Ritonavir and Rilpivirine	Darunavir, Ritonavir and Rilpivirine	St Stephens Aids Trust	marketed	Antiretroviral combination (protease inhibitor + NNRTI)	HIV protease, HIV reverse transcriptase
Darunavir, Ritonavir and Etravirine	Darunavir, Ritonavir and Etravirine	Imperial College London	marketed	Antiretroviral combination (protease inhibitor + NNRTI)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI + NNRTI) class)

1. GlaxoSmithKline · 2 drugs in this class
2. Clinical Trial Agency of HIV Study Group · 1 drug in this class
3. Hospital Clinic of Barcelona · 1 drug in this class
4. Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · 1 drug in this class
5. National Center for AIDS/STD Control and Prevention, China CDC · 1 drug in this class
6. Peking Union Medical College Hospital · 1 drug in this class
7. Sheba Medical Center · 1 drug in this class
8. Azienda Ospedaliera San Gerardo di Monza · 1 drug in this class
9. University of KwaZulu · 1 drug in this class